IMPORTANT SAFETY INFORMATION:
Eliphos™ (Calcium Acetate, USP) is indicated for the control of hyperphosphatemia in end stage renal failure and does not promote aluminum absorption. Eliphos™ is administered orally, and when given with food, combines with dietary phosphate to form insoluble calcium phosphate complexes that are eliminated from the body, thereby reducing phosphorus absorption, helping to prevent excess blood phosphorus levels. Patients should have serum calcium levels closely monitored and their dose of Eliphos™ adjusted or terminated to bring levels to normal. Eliphos™ is contraindicated in patients with hypercalcemia. No other calcium supplements should be given concurrently with Eliphos™. Eliphos™ is well tolerated and has an excellent safety profile. Nausea, hypercalcemia, and pruritus (itching) have occasionally been reported during Eliphos™ therapy.
For full prescribing information, please click here.

If you do not have Adobe® Acrobat® Reader for viewing the pdfs shown above, you may download it free of charge by clicking here.